Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

259.02 -3.87 (-1.47%)
Streaming Delayed Price Updated: 1:02 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 213,890
Open 262.88
Bid (Size) 258.79 (2)
Ask (Size) 259.27 (2)
Prev. Close 262.89
Today's Range 258.78 - 265.51
52wk Range 141.97 - 274.93
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Via Benzinga

Performance

YTD
+32.88%
+32.88%
1 Month
+1.11%
+1.11%
3 Month
+75.73%
+75.73%
6 Month
+57.79%
+57.79%
1 Year
+43.80%
+43.80%

More News

Read More
The 3 Best Gene Editing Stocks to Buy in August 2024
Via InvestorPlace
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
How Is The Market Feeling About Alnylam Pharmaceuticals?
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
Via Benzinga
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
Via Investor's Business Daily
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Via Benzinga
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Via Benzinga
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Stock Is a Blockbuster Biopharma In the Making
Via InvestorPlace
35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success.
Via InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
Via InvestorPlace
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
Via The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
Via Benzinga
Topics ETFs
$100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
Via Benzinga
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
Privacy Policy  |  Terms of Use  |  MNG Corporate Site Map  |  Copyright